The Prospective Segeberg Registry for Mitral Transcatheter Edge-to-Edge Repair
Launched by SEGEBERGER KLINIKEN GMBH · Jun 22, 2025
Trial Information
Current as of September 30, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a treatment for a heart condition called severe mitral regurgitation, where the heart’s mitral valve doesn’t close properly, causing blood to flow backward. The treatment being studied is called Mitral Transcatheter Edge-to-Edge Repair (M-TEER), a minimally invasive procedure that helps fix the valve without open-heart surgery. The trial aims to follow patients who have this procedure to learn more about how well it works and how patients do afterward.
If you have severe mitral regurgitation and are scheduled to have the M-TEER procedure, you might be eligible to join this study. There are no specific restrictions besides having the condition and undergoing the procedure, and people of all genders and a wide age range can participate. By joining, you can expect regular follow-up visits to monitor your health and see how the treatment is helping you over time. This study is currently recruiting patients in Bad Segeberg, and the information gathered may help improve care for future patients with this heart condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with severe MR undergoing M-TEER
- Exclusion Criteria:
- • None
About Segeberger Kliniken Gmbh
Segeberger Kliniken GmbH is a leading healthcare organization specializing in innovative clinical research and patient care. With a commitment to advancing medical science, the company conducts a range of clinical trials aimed at developing new therapies and improving treatment outcomes across various medical disciplines. Backed by a team of experienced professionals and state-of-the-art facilities, Segeberger Kliniken GmbH collaborates with academic institutions and industry partners to ensure the highest standards of clinical excellence and ethical practices. Their dedication to patient safety and scientific integrity positions them as a trusted sponsor in the field of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bad Segeberg, Schleswig Holstein, Germany
Patients applied
Trial Officials
Holger Nef, Prof., MD
Study Director
Herzzentrum Segeberger Kliniken GmbH
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported